文献速递心血管MR

心肌T1 mapping与细胞外容积分数在心力衰竭中的预后价值:一项Meta分析

Prognostic Value of Myocardial T1 Mapping and Extracellular Volume Fraction in Heart Failure: A Meta-Analysis.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-08-29

该Meta分析纳入19项研究共5384例心力衰竭患者,评估心肌T1 mapping和细胞外容积分数(ECV)的预后价值。不良结局患者天然T1和ECV均高于无不良结局者(加权均数差分别为41.17 ms和4.73%)。ECV在全心力衰竭谱系中均有稳定预后意义,天然T1预测价值弱于ECV,尤其在射血分数保留的心力衰竭中无显著预后价值。

要点

  • 不良结局患者天然T1较无不良结局者高41.17 ms,ECV高4.73%。
  • ECV每升高1%的HR为1.20,二分法HR为2.62,全HF谱系均阳性。
  • 天然T1在射血分数保留的心力衰竭中无显著预后价值(P>0.05)。

核心结论

  • ECV在全部心力衰竭谱系中具有一致的预后意义,不受心衰类型、临床特征和病因影响;天然T1预测价值弱于ECV,尤其在射血分数保留的心力衰竭中。

研究设计与样本

  • 系统检索PubMed、Web of Science和SCOPUS的Meta分析,纳入19项研究共5384例患者(56.2%男性),评估T1 mapping在射血分数降低和保留的心力衰竭中的预后价值,汇总基线水平、均数差和HR。

诊断标准与关键数值

  • 不良结局(死亡、心衰相关事件或复合结局)患者较无不良结局者天然T1加权均数差高41.17 ms、ECV高4.73%。全心衰组:ECV每升高1%的HR为1.20(95%CI 1.13-1.28),ECV升高>1%的HR为1.56(95%CI 1.40-1.75),ECV二分法HR为2.62(95%CI 2.07-3.32);天然T1每升高1 ms的HR为1.02(95%CI 1.01-1.03),天然T1升高≥10 ms的HR为1.08(95%CI 1.05-1.11),天然T1二分法HR为2.93(95%CI 2.03-4.23),均P<0.05。

临床应用与阅片要点

  • 作者结论认为ECV在全部心衰谱系中具有一致预后意义,天然T1预测价值较弱,尤其在射血分数保留的心力衰竭中无显著预后价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Heart failure (HF) is a global health burden. Myocardial fibrosis is a crucial promotor in HF progression which can be characterized noninvasively by cardiac magnetic resonance T1 mapping.

OBJECTIVES: This study aims to systemically evaluate the prognostic value of myocardial T1 mapping and extracellular volume fraction (ECV) covering the entire spectrum of HF through a meta-analysis.

METHODS: We searched PubMed, Web of Science, and SCOPUS for studies examining the prognostic value of T1 mapping in HF with reduced and preserved ejection fraction. Baseline level, mean difference, and HRs were pooled for meta-analysis. Subgroup analyses were conducted according to HF subtypes and clinical characteristics.

RESULTS: Nineteen studies with 5,384 patients (56.2% male) were included in the analysis. Patients with adverse outcomes (mortality, HF-related event, or composite outcome) had higher native T1 and ECV values than those without (weighted mean difference: 41.17 ms and 4.73%, respectively). Both native T1 and ECV were positively associated with endpoints for the entire HF group (HR of 1% increase in ECV: 1.20 [95% CI: 1.13-1.28]; HR of >1% increase: 1.56 [95% CI: 1.40-1.75]; HR binary: 2.62 [95% CI: 2.07-3.32]; HR of 1-ms increase in native T1: 1.02 [95% CI: 1.01-1.03]; HR of ≥10-ms increase: 1.08 [95% CI: 1.05-1.11]; HR binary: 2.93 [95% CI: 2.03-4.23], all P < 0.05). For subgroup cohorts, native T1 had no significant prognostic value in HF with preserved ejection fraction (P > 0.05). Younger patients with HF with severe cardiac insufficiency (NYHA functional class III-IV), persistently increasing ECV, or negative late enhancement who exhibited abnormal T1 mapping were at higher risk of adverse outcomes.

CONCLUSIONS: ECV has consistent prognostic implications across HF spectrum, regardless of HF types, clinical characteristics, and various etiology. Native T1 is less predictive than ECV, particularly in HF with preserved ejection fraction.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang H, Yang W, Zhou D, et al. Prognostic Value of Myocardial T1 Mapping and Extracellular Volume Fraction in Heart Failure: A Meta-Analysis. JACC Cardiovasc Imaging. 2025. PMID: 40884516. doi:10.1016/j.jcmg.2025.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。